Robert Wasserman
Stock Analyst at Benchmark
(3.53)
# 911
Out of 4,915 analysts
113
Total ratings
46.3%
Success rate
6.41%
Average return
Main Sectors:
Stocks Rated by Robert Wasserman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TECH Bio-Techne | Reiterates: Buy | $75 | $57.20 | +31.12% | 7 | Jun 5, 2025 | |
| KMDA Kamada | Reiterates: Buy | $15 | $7.52 | +99.41% | 2 | May 15, 2025 | |
| OABI OmniAb | Reiterates: Buy | $6 | $1.95 | +208.48% | 9 | May 12, 2025 | |
| ITGR Integer Holdings | Maintains: Buy | $150 → $140 | $108.22 | +29.37% | 11 | Apr 25, 2025 | |
| XOMA XOMA Royalty | Initiates: Buy | $35 | $25.25 | +38.61% | 1 | Apr 17, 2025 | |
| IPA ImmunoPrecise Antibodies | Reiterates: Speculative Buy | $3 | $1.72 | +74.42% | 6 | Apr 1, 2025 | |
| ABCL AbCellera Biologics | Reiterates: Hold | n/a | $4.52 | - | 6 | Mar 3, 2025 | |
| HALO Halozyme Therapeutics | Reiterates: Buy | $75 | $60.86 | +23.23% | 9 | Feb 20, 2025 | |
| BLFS BioLife Solutions | Reiterates: Buy | $30 | $21.61 | +38.82% | 6 | Dec 19, 2024 | |
| ANEB Anebulo Pharmaceuticals | Reiterates: Speculative Buy | $8 | $2.82 | +183.69% | 6 | Nov 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Speculative Buy | $5 | $3.67 | +36.22% | 3 | Nov 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $8 → $12 | $5.95 | +101.85% | 17 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Hold | n/a | $2.73 | - | 7 | Nov 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Hold | n/a | $121.44 | - | 3 | Aug 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Speculative Buy | $12 | $0.29 | +4,081.18% | 6 | Jul 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $45 | $41.35 | +8.83% | 6 | May 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Speculative Buy | $4 | $5.16 | -22.48% | 1 | Mar 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Speculative Buy | $4 | $0.21 | +1,800.23% | 1 | Mar 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Speculative Buy | $75 | $1.84 | +3,976.09% | 2 | Apr 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $202.76 | - | 3 | Oct 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $580 | $481.62 | +20.43% | 1 | Jul 16, 2021 |
Bio-Techne
Jun 5, 2025
Reiterates: Buy
Price Target: $75
Current: $57.20
Upside: +31.12%
Kamada
May 15, 2025
Reiterates: Buy
Price Target: $15
Current: $7.52
Upside: +99.41%
OmniAb
May 12, 2025
Reiterates: Buy
Price Target: $6
Current: $1.95
Upside: +208.48%
Integer Holdings
Apr 25, 2025
Maintains: Buy
Price Target: $150 → $140
Current: $108.22
Upside: +29.37%
XOMA Royalty
Apr 17, 2025
Initiates: Buy
Price Target: $35
Current: $25.25
Upside: +38.61%
ImmunoPrecise Antibodies
Apr 1, 2025
Reiterates: Speculative Buy
Price Target: $3
Current: $1.72
Upside: +74.42%
AbCellera Biologics
Mar 3, 2025
Reiterates: Hold
Price Target: n/a
Current: $4.52
Upside: -
Halozyme Therapeutics
Feb 20, 2025
Reiterates: Buy
Price Target: $75
Current: $60.86
Upside: +23.23%
BioLife Solutions
Dec 19, 2024
Reiterates: Buy
Price Target: $30
Current: $21.61
Upside: +38.82%
Anebulo Pharmaceuticals
Nov 19, 2024
Reiterates: Speculative Buy
Price Target: $8
Current: $2.82
Upside: +183.69%
Nov 12, 2024
Reiterates: Speculative Buy
Price Target: $5
Current: $3.67
Upside: +36.22%
Nov 7, 2024
Maintains: Buy
Price Target: $8 → $12
Current: $5.95
Upside: +101.85%
Nov 4, 2024
Reiterates: Hold
Price Target: n/a
Current: $2.73
Upside: -
Aug 5, 2024
Reiterates: Hold
Price Target: n/a
Current: $121.44
Upside: -
Jul 11, 2024
Reiterates: Speculative Buy
Price Target: $12
Current: $0.29
Upside: +4,081.18%
May 29, 2024
Reiterates: Buy
Price Target: $45
Current: $41.35
Upside: +8.83%
Mar 7, 2024
Reiterates: Speculative Buy
Price Target: $4
Current: $5.16
Upside: -22.48%
Mar 6, 2024
Reiterates: Speculative Buy
Price Target: $4
Current: $0.21
Upside: +1,800.23%
Apr 6, 2023
Reiterates: Speculative Buy
Price Target: $75
Current: $1.84
Upside: +3,976.09%
Oct 24, 2022
Downgrades: Hold
Price Target: n/a
Current: $202.76
Upside: -
Jul 16, 2021
Initiates: Buy
Price Target: $580
Current: $481.62
Upside: +20.43%